TIP or BEP for Intermediate or Poor Risk Testicular Cancer?: ASCO 2018 GU Highlights (BMIC-061)

Chemotherapy for testicular cancer patients with 'intermediate risk'Подробнее

Adj. Docetaxel for Int. or High Risk Prostate Cancer After Rad: ASCO 2018 GU Highlights (BMIC-060)Подробнее

Testicular Cancer Highlights from ESMO 2022Подробнее

Kidney Cancer Conference Highlights from ASCO GU 2023Подробнее

Highlights in penile cancer at ASCO GU 2023Подробнее

Highlights in bladder cancer from ASCO 2022Подробнее

New PARP Inhibitor Abiraterone Combo in Met Prostate Cancer: ASCO 2018 GU Highlights (BMIC-058)Подробнее

Testicular Cancer Conference Highlights from ASCO GU 2023Подробнее

Chemotherapy for Testicular Cancer Patients with 'Intermediate Risk' - Constantine AlbanyПодробнее

GU Cancers: Best of ASCO - M. Milowsky - 20180425Подробнее

What is Positive Predictive Value of PET PSMA in Prostate Cancer? ASCO 2018 GU Highlights (BMIC-059)Подробнее

GU ASCO 2023 Highlights - OncBrothers (Rohit and Rahul Gosain) with Dr. Petros GrivasПодробнее

Alison Birtle: ASCO GU highlightsПодробнее

Testicular Cancer Conference Highlights from ASCO 2022Подробнее

Treatment of Testicular Cancer (Seminoma)Подробнее

2022 GU ASCO Kidney Cancer HighlightsПодробнее

2022 GU ASCO Bladder Cancer HighlightsПодробнее

Understanding Testicular CancerПодробнее

GU ASCO Symposium 2022 SummaryПодробнее